Treatment of metastatic colorectal cancer (CRC) with traditional 5-fluorouracil (5FU)-based chemotherapy has been modified, with addition of oxaliplatin, irinotecan and monoclonal antibodies targeting vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR). This evidence concerns the gene VEGFA and metastatic colorectal cancer.